BioWorld Asia

Dec. 22, 2004

Pharmos Crashes On Data From Phase III Brain Study

Once high on Pharmos Corp.'s cannabinoid-receptor drug for brain injury, investors came down hard following news that the compound failed in a pivotal Phase III trial.(BioWorld International) Read More

CAT Wins Court Battle Over Humira; Abbott Logs Appeal

Gene Therapy Boosts Hope For Blood Disease Therapies

Eyeing Cancer Drugs, Aphton Acquiring Igeneon For $81M

Europe Tackles Distinction In Similar Biotech Orphan Drugs

Phytopharm Product, Not Good For Pharma, Aimed At Foods

'Right Time': Bavarian Nordic To Form Cancer Vaccine Unit In U.S.

NicOx Taking Lead CINOD Into Phase III Osteoarthritis Program

Metabolic Jumps, Slides On Trial Data, Analyst Criticism

Santhera Raises Additional EUR7M In Second Closing Of Financing

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 8, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...

Woman taking medication for mental illness

Autobahn on the fast track with bipolar thyroid agonist

BioWorld

Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...